29/05/2024
Fingers crossed this is approved soon 🤞🤞
Researchers we funded have discovered a new way to target cancer cells that could lead to longer-lasting protection for people with breast cancer.
Professor Pascal Meier and his team at the Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research, London targeted a protein called RIPK1. This protein plays a key role in helping cancer cells survive and remain undetected in the body.
They used a new and innovative technology called proteolysis targeting chimera (PROTAC) to successfully destroy RIPK1 in cancer cells.
Getting rid of RIPK1 triggers a process known as immunogenic cell death in cancer cells. This mobilises the immune system to destroy any remaining cancer cells that have escaped treatment or become resistant to drugs.
The researchers showed that targeting RIPK1 with this new technology activates the immune system after radiotherapy and immunotherapy treatment in mice. This boosted the overall response to treatment and could potentially offer longer protection against the disease.
The researchers hope this approach could be effective for a range of different cancers, including triple negative breast cancer.
https://breastcancernow.org/about-us/research-news/new-way-to-kill-cancer-cells-could-lead-to-longer-lasting-protection-for-people-with-breast-cancer/?utm_source=facebook&utm_medium=social&utm_campaign=research&utm_content=290524pascal